Course Summary

Expiration Date: 12/08/2028

Heart failure remains a leading cause of morbidity, mortality, and hospitalizations despite advances in guideline-directed therapy. Sodium–glucose cotransporter 2 (SGLT2) inhibitors have transformed HF care, and sotagliflozin—the first dual SGLT2/SGLT1 inhibitor—adds a novel therapeutic dimension through combined renal, metabolic, and potential myocardial effects. Trials such as SOLOIST-WHF and SCORED show sotagliflozin reduces cardiovascular death, HF hospitalizations, and urgent visits while improving quality of life, with benefits across HF phenotypes and in high-risk patients with type 2 diabetes or chronic kidney disease. This course reviews HF pathophysiology, current standards of care, and the evidence supporting dual SGLT inhibition, emphasizing sotagliflozin’s role, safety, and integration into modern management.

Course Format

Homestudy

Course Syllabus

  • Introduction
  • Pathophysiology of Heart Failure
  • Clinical Course of Heart Failure
  • Treatment: Standard of Care Based on Guidelines
  • SGLT Inhibitors in Heart Failure: Class Overview and Sotagliflozin’s Added Dimension
    • Mechanisms of Action
    • Available SGLT2 Inhibitors
    • Sotagliflozin: Dual SGLT2 and SGLT1 Inhibition
  • Sotagliflozin: Place in Therapy for Heart Failure
    • Dosing and Administration
    • Renal Function and Special Populations
    • Contraindications and Precautions
    • Safety and Monitoring
    • Practical Use in Contemporary Care
  • Evidence Supporting Sotagliflozin in Heart Failure
  • Clinical Pearls: Sotagliflozin in Heart Failure
    • Unique Mechanism and Patient Selection
    • Ease of Use and Early Initiation
    • Impact on Symptoms and Quality of Life
    • Common and Notable Adverse Effects
    • Serious Risks and “Sick-Day” Rules
    • Integration into Heart-Failure Therapy (and Diuretic Strategy)
  • JOURNAL CLUB: SOTAGLIFLOZIN AND QUALITY OF LIFE IN WORSENING HEART FAILURE
    • Background
    • Methods
    • Results
    • Discussion
  • Summary

Authors

Richard Daniels, PharmD, BCPS

Richard “Cole” Daniels earned his Doctor of Pharmacy(PharmD) from the Skaggs School of Pharmacy at the University of Montana in 2018. Throughout pharmacy school he completed a 3-year internship at Community Medical Center in Missoula, Montana in which he gained valuable experience in an acute care setting. Cole currently serves as a psychiatric clinical staff pharmacist at the Montana State Hospital. He has over 11 years of pharmacy experience having worked in several settings including retail, acute care, and inpatient psychiatric care. Cole has a diverse set of interests. However, acute care medicine, infectious disease, pain management, and asthma/COPD are a primary focus of his at the Montana State Hospital. He obtained board certification as a certified pharmacotherapy specialist in the Spring of 2022.

Luke Almos, PharmD

Luke Almos will be graduating from the University of Montana’s Skaggs School of Pharmacy in the spring of 2026. He has 3 years of experience in retail pharmacy, with interests in inpatient and ambulatory patient care. He has actively contributed to research and educational materials throughout his undergraduate education. His primary interests are metabolic disorders, anticoagulation management, and providing patient education. Luke’s primary goal is to help implement initiatives and provide education resulting in impactful patient care across all specialties.